ScinoPharm Taiwan Ltd. is a pharmaceutical company based in Taiwan with a medium risk rating score of 27.2. Specializing in the manufacturing of specialty and generic drugs, the company also offers services in chemicals, biological technology, and active pharmaceutical ingredients. With a focus on ESG principles, ScinoPharm is dedicated to sustainable practices in its operations. The company's growth strategy includes potential mergers and acquisitions to enhance its research, development, and marketing capabilities. Revenue primarily comes from the sales of Active Pharmaceutical Ingredient and injection products.